MEGAN SCOTT: Open Payments
NPI 1740924422 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,200 in 73 payments from 22 companies in 2025. Trend: 2023 $1,574 · 2024 $1,651 · 2025 $1,200
Food & beverage: $1,200
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $224 |
| Lilly USA, LLC | 11 | $146 |
| PFIZER INC. | 6 | $102 |
| Novo Nordisk Inc | 4 | $78 |
| ViiV Healthcare Company | 3 | $71 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| SANOFI-AVENTIS U.S. LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
Products named: MOUNJARO, REXULTI, VRAYLAR, APRETUDE, CAPLYTA, TZIELD, UBRELVY, Ozempic.
Industry payments across NE — which companies pay providers there.
